The ResMed Inc (ASX: RMD) share price has had a stellar run this year and is currently nudging record highs.
Since the start of the year, shares in the medical device have soared more than 45%.
In comparison, the broader S&P/ASX200 Index (ASX: XJO) has only managed to gain 13% in 2021.
In the last month, shares in ResMed have continued their massive bull run.
Let’s take a look at why investors have continued to push the ResMed share price higher in the past month.
What’s been driving the ResMed share price higher?
There have been several catalysts that have helped propel the ResMed share price higher in the last 30 days.
The first catalyst can be traced back to early last month when the medical device company released its full-year results for FY21.
ResMed reported an 8% increase in full year to US$3.2 billion and a 13% jump in non-GAAP net income to US$780.6 million.
The company also upped its quarterly dividend by 8% to US42 cents per share.
However, ResMed did flag that profit margins could be under pressure in the future.
The second catalyst that shot the ResMed share price to record highs was the launch of a new key product.
Last month, the medtech giant launched its next-generation positive airway pressure (PAP) device, AirSense 11, in the United States.
ResMed noted that the product’s remote software updates and new tailored features could make it the gold standard for treating sleep apnoea.
Outlook for the ResMed share price
ResMed is a global leader in respiratory medical devices, particularly targeted towards the treatment of sleep apnoea.
In addition, the company also produces invasive and non-invasive ventilators that are used to boost the oxygen intake of patients.
Shares in ResMed have benefited from the company’s strong revenue and earnings growth.
The medtech giant has managed to maintain growth by providing industry-leading products, software and continued investment in research and development.
A recent note from leading broker Morgans indicates that the ResMed share price could continue its massive bull run.
Analysts expect the positive form to continue over the medium term, initiating a $41.34 price target on ResMed’s shares.
At the time of writing, the ResMed share price is trading slightly lower for the day at $39.75.
The post Will the ResMed (ASX:RMD) share price continue its massive bull run? appeared first on The Motley Fool Australia.
Should you invest $1,000 in ResMed right now?
Before you consider ResMed, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- Top broker names 3 ASX 200 shares to buy
- 3 ASX growth shares that analysts love
- Revealed: The biggest shocker from results season
- 2 top blue chip ASX shares rated as buys
- Why Domain, Money3, ResMed, & Steadfast shares are charging higher
Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/38uRv9W
Leave a Reply